Jarl E. Mooyaart

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Interindividual HLA evolutionary divergence in mismatched unrelated donor allo-HCT for malignant hematological disorders.

Interindividual HLA evolutionary divergence in mismatched unrelated donor allo-HCT for malignant hematological disorders.

Journal: Blood advances

Published: March 06, 2026

Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.

Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.

Journal: Bone marrow transplantation

Published: March 02, 2026

Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma.

Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma.

Journal: Haematologica

Published: January 15, 2026

OUTCOMES OF PATIENTS OVER 70 YEARS TREATED WITH BREXU-CEL FOR R/R MANTLE CELL LYMPHOMA: A STUDY FROM THE CTIWP OF EBMT.

OUTCOMES OF PATIENTS OVER 70 YEARS TREATED WITH BREXU-CEL FOR R/R MANTLE CELL LYMPHOMA: A STUDY FROM THE CTIWP OF EBMT.

Journal: Blood advances

Published: December 12, 2025

Outcomes of patients over 70 years treated with brexu-cel for R/R mantle cell lymphoma: a study from the CTIWP of EBMT.

Outcomes of patients over 70 years treated with brexu-cel for R/R mantle cell lymphoma: a study from the CTIWP of EBMT.

Journal: Blood advances

Published: December 12, 2025

Current capacity and gaps in viral vector manufacturing: a survey of centers associated with CTIWP of EBMT, NXTGEN-hightech, DARE-NL, T2EVOLVE, and GoCART coalition.

Current capacity and gaps in viral vector manufacturing: a survey of centers associated with CTIWP of EBMT, NXTGEN-hightech, DARE-NL, T2EVOLVE, and GoCART coalition.

Journal: Bone marrow transplantation

Published: July 10, 2025

Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation.

Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation.

Journal: British journal of haematology

Published: March 24, 2025

CAR-T cell manufacturing failures and out-of-specification products in the real-world setting: A survey from the EBMT cellular therapy and immunobiology working party.

CAR-T cell manufacturing failures and out-of-specification products in the real-world setting: A survey from the EBMT cellular therapy and immunobiology working party.

Journal: Bone marrow transplantation

Published: February 12, 2025

The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT.

The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT.

Journal: Blood reviews

Published: November 10, 2024

Current use of donor lymphocyte infusions after allogenic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT.

Current use of donor lymphocyte infusions after allogenic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT.

Journal: Bone marrow transplantation

Published: October 30, 2024

Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT.

Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT.

Journal: Bone marrow transplantation

Published: June 24, 2024

Nurses' reported training needs for advanced cell therapies: a survey on behalf of the Nurses Group of the EBMT.

Nurses' reported training needs for advanced cell therapies: a survey on behalf of the Nurses Group of the EBMT.

Journal: Clinical hematology international

Published: May 17, 2024

Showing 1-12 of 24

Last Updated: 09/26/2026